During the 2025 Society Of Breast Imaging Symposium, CMR Molecular Imaging invites you to visit its exhibit at Booth #347.
MBI detects additional cancers compared with conventional imaging in women with dense breasts and those with elevated risk of breast cancer. Its role as an imaging biomarker of cancer risk and in assessing neoadjuvant chemotherapy response is growing. Radiation risk is minimal; benefit-to-risk ratio is similar to that of mammography. MBI is low cost, well tolerated, and easily adapted into clinical practice. Dibble et al. AJR 2020; 215:277–284
RELATED TALKS AT SBI
Thursday, April 24, 2025
1:30 PM – 2:30 PM
Breast MBI and Breast CT: Latest Science
Katie N. Hunt, MD, FSBI, Breast Radiologist Mayo Clinic College of Medicine, Rochester
Shadi Aminololama-Shakeri, MD, FSBI, University of California Davis Medical Center
LumaGEM®
Ultra low dose imaging O’Connor EUSOBI poster 2019
250% ICDR Rhodes et al. AJR 2015
2x estimated net deaths averted Brown and Covington Radiology: Imaging Cancer 2019